BostonGene, WellDyne announce strategic partnership

By The Science Advisory Board staff writers

January 12, 2022 -- BostonGene Corporation and WellDyne have formed a strategic partnership to improve therapeutic decision-making for cancer patients. Using BostonGene's tumor portrait test, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in a variety of cancers.

The BostonGene tumor portrait test, based on integrated genomic and transcriptomic analysis, reveals key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.

The test can significantly increase the correct identification of patients who respond to immunotherapy and may help other patients avoid unnecessary adverse events, the companies said. It combines precise data processing and proprietary algorithms to generate easy-to-understand tumor schematics, including BostonGene's molecular functional portrait, a personalized tumor map to guide treatment decision-making that tailors individualized treatments and streamlines treatment costs.

No financial details of the partnership were disclosed.

BostonGene Corporation is a biomedical software company that is committed to defining optimal, precision medicine-based therapies for cancer patients. WellDyne leverages precision medicine's targeted approach to predict how a patient will respond to specific drugs.

Copyright © 2022
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here